- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01124240
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene (ExCentric)
Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene
Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.
Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).
After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2065
- Recruiting
- Royal North Shore Hospital
-
Contact:
- Sally McCowatt, Rn
- Phone Number: 61299265049
- Email: smccowat@nsccahs.health.nsw.gov.au
-
Contact:
- Helen Wheeler, MBBS
- Phone Number: 61299267111
- Email: hrwheeler@optusnet.com.au
-
Principal Investigator:
- Helen Wheeler, MBBS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed supratentorial GBM (WHO Grade IV,including GBM subtypes, e.g. gliosarcoma), histopathologically confirmed by central assessment as part of the screening for the CENTRIC trial.
- Males or females ≥18 years of age.
- Proven unmethylated MGMT gene promoter status, centrally assessed as part of the screening for the CENTRIC trial.
- Written informed consent for the present trial obtained before undergoing any study-related activities. The informed consent also allows access to all information obtained during the screening for the CENTRIC trial, notably the result of the MGMT testing.
- Available post-operative Gd-MRI performed within <48 hours after surgery (in case it was not possible to obtain a Gd-MRI within <48 hours post surgery, a Gd-MRI is to be performed prior to randomization).
- Stable or decreasing dose of steroids for >5 days prior to randomization.
- ECOG PS of 0-1.
- Interval of ≥2 weeks but ≤7 weeks after surgery or biopsy before first administration of study treatment.
Meets one of the following RPA classifications:
- Class III (age <50 years and ECOG PS 0).
Class IV (meeting one of the following criteria:
- Age <50 years and ECOG PS 1 or
- Age ≥50 years, underwent prior partial or total tumor resection, Mini Mental State Examination [MMSE]≥27).
Class V (meeting one of the following criteria:
- Age ≥50 years and underwent prior partial or total tumour resection, MMSE <27 or
- Age ≥50 years and underwent prior tumor biopsy only).
Laboratory values (within 2 week prior to randomization):
- Absolute neutrophil count ≥1500/mm3.
- Platelets ≥ 100,000/mm3.
- Creatinine ≤1.5 x upper limit of normal (ULN) or creatinine clearance rate ≥60 mL/min
- Prothrombin time (PT) international normalized ratio (INR) and partial thromboplastin time (PTT) within normal limits.
- Hemoglobin ≥10 g/dL.
- Total bilirubin ≤1.5 x the ULN.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN(except when attributable to anticonvulsants).
- Alkaline phosphatase ≤ 2.5 x ULN.
Exclusion criteria
Subjects are not eligible for this study, if they fulfill one or more of the following exclusion criteria:
- Prior chemotherapy within the last 5 years.
- Prior RTX of the head.
- Receiving concurrent investigational agents or has received an investigational agent(s) within the past 30 days prior to the first dose of Cilengitide .
- Prior systemic antiangiogenic therapy.
- Placement of Gliadel® wafer at surgery.
- Treatment with a prohibited concomitant medication.
- Planned surgery for other diseases (e.g. dental extraction).
- History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months of enrollment.
- History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for ≥ 5 years are eligible for this study.
- History of coagulation disorder associated with bleeding or recurrent thrombotic events.
- Clinically manifest myocardial insufficiency (NYHA III, IV) or history of myocardial infarction during the past 6 months. Uncontrolled arterial hypertension.
- Concurrent illness, including severe infection, which may jeopardize the ability of the subject to receive the procedures outlined in this protocol with reasonable safety.
- Subject is pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at screening) or is currently breast-feeding, anticipates becoming pregnant/ impregnating their partner during the study or within 6 months after study participation, or subject does not agree to follow acceptable methods of birth control, such as hormonal contraception, intra-uterine pessar, condoms or sterilization, to avoid conception during the study and for at least 6 months after receiving the last dose of study treatment.
- Current alcohol dependence or drug abuse.
- Known hypersensitivity to the study treatment.
- Legal incapacity or limited legal capacity.
- Inability to undergo Gd-MRI.
- Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Signs and symptoms suggestive of transmissible spongiform encephalopathy, or of family members who suffer(ed) from such.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
12 month progression free survival
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response
Time Frame: 3 years
|
MRI review
|
3 years
|
Toxicity
Time Frame: 3 years
|
Utilising NCI CTC v 3.0
|
3 years
|
Peripheral WBC MGMT modulation
Time Frame: 3 years
|
Blood collection and analysis
|
3 years
|
biomarker correlation with response
Time Frame: 3 years
|
using multiplex bioassay analysis
|
3 years
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
- Procarbazine
Other Study ID Numbers
- 0910259M
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Jonsson Comprehensive Cancer CenterGlaxoSmithKline; NovartisActive, not recruitingNewly Diagnosed Glioblastoma MultiformeUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
Samus Therapeutics, Inc.TerminatedRecurrent Glioblastoma Multiforme (GBM) | Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma | Grade 3 or 4 Astrocytoma | Glioblastoma SurgeryUnited States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Celularity IncorporatedTerminatedGlioblastoma Multiforme | Molecular Mechanisms of Pharmacological Action | Giant Cell Glioblastoma | Astrocytoma, Grade IV | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Cyclophosphamide | Immunosuppressive Agents | Immunologic Factors | Antiviral... and other conditionsUnited States
-
Sapience TherapeuticsRecruitingBreast Cancer | Glioblastoma | Prostate Cancer | Brain Cancer | Glioblastoma Multiforme | GBM | Metastatic Breast Cancer | Recurrent Glioblastoma | Metastatic Melanoma | Metastatic Prostate Cancer | Prostate Cancer Metastatic | Newly Diagnosed Glioblastoma | Melanoma Stage IV | Melanoma RecurrentUnited States, United Kingdom
-
St. Jude Children's Research HospitalNovartis PharmaceuticalsActive, not recruitingGlioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditionsUnited States
-
Sue O'DorisioNational Cancer Institute (NCI); Ride for KidsWithdrawnRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Untreated Childhood Brain Stem Glioma | Untreated Childhood Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Adult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma and other conditionsUnited States
Clinical Trials on Cilengitide
-
Merck KGaA, Darmstadt, GermanyCompleted
-
EMD SeronoCompletedGlioblastoma MultiformeUnited States
-
New Approaches to Brain Tumor Therapy ConsortiumNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Indiana University School of MedicineNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant ConditionUnited States
-
National Cancer Institute (NCI)Terminated
-
Centre Oscar LambretCompletedDiffuse Intrinsic Pontine GliomaFrance
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Universitätsmedizin MannheimHeidelberg UniversityUnknownLung Cancer | Brain and Central Nervous System TumorsGermany
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL)... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Choroid Plexus Tumor | Childhood Craniopharyngioma | Childhood Ependymoblastoma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma and other conditionsUnited States